Biopharma research platform developing tumor ecosystem disruptors that target cancer drug resistance across multiple cell types.
Alixia is a biopharma company developing a portfolio of therapeutic compounds targeting the tumor microenvironment as an ecological system rather than a single mutation. Their research platform integrates biology, biophysics, computational chemistry, and clinical input to identify lead compounds that disrupt metabolic and inflammatory triggers in both cancer and quasi-cancerous cells. Current programs span various stages of preclinical development addressing multiple age-related diseases at the intersection of cancer, aging, and immunity. Alixia is a product of Alixia.